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TO THE EDITOR
The mitogen-activated protein kinase
signaling pathway plays an important
role in cell proliferation, differentiation
and survival and is frequently altered in
cancer. Genetic mechanisms that acti-
vate the mitogen-activated protein-
kinase pathway vary among subtypes
of melanoma when tumors are classi-
fied according to a combination of sun
exposure and anatomic site (Maldona-
do et al., 2003; Curtin et al., 2005,
2006). NRAS (neuroblastoma ras viral
oncogene homolog), which is part of
the RAS/RAF/mitogen-activated protein-
kinase signaling cascade, is mutated in
10–20% of melanomas regardless of
anatomic site. In contrast, v-raf murine
sarcoma viral oncogene homolog B1
(BRAF) mutations are frequent (about
60%) in melanomas occurring on skin
without signs of chronic sun-induced
damage (CSD) (non-CSD melanomas),
but infrequent in melanomas that occur
on skin showing evidence of CSD as
well as on sun-protected skin such as
the palms, soles, or subungual sites
(acral melanomas), and on mucosal
membranes (mucosal melanomas) (Mal-
donado et al., 2003; Curtin et al., 2005).
We have recently reported increased
copy numbers of chromosome 4q12
and identified v-kit Hardy-Zuckerman
4 feline sarcoma viral oncogene homo-
log (KIT) as a somatic target that is
activated in CSD, acral, and mucosal
melanoma. This genomic region con-
tains several additional genes that are
involved in other types of cancer,
including the platelet-derived growth
factor a receptor (PDGFRA). PDGFRA
is a receptor tyrosine kinase, which is
activated by mutations or small dele-
tions in a subset of gastrointestinal
stroma tumors (Heinrich et al., 2003b)
and childhood acute myeloid leukae-
mia’s (Hiwatari et al., 2005) as well as
fusion with FIP1L1 in hypereosinophilic
syndrome (Cools et al., 2003) and
systemic mastocytosis associated with
eosinophilia (Pardanani et al., 2003).
Mutation of PDGFRA or KIT occurs
infrequently in most solid tumors with
the exception of gastrointestinal stroma
tumors (Sihto et al., 2005). In gastro-
intestinal stroma tumors, mutations in
PDGFRA and KIT are mutually exclu-
sive (Heinrich et al., 2003a, b) and
tumors with either mutation can show
responses with kinase inhibitors such as
imatinib, dasatinib, and sunitinib (Hein-
rich et al., 2003a; Corless et al., 2006;
Schittenhelm et al., 2006). PDGFRA has
been found to be overexpressed in some
melanomas (Barnhill et al., 1996), rais-
ing the possibility that it could also be a
target of somatic mutations in some
melanomas. To date, a limited mutation
analysis of primary tumors did not find
mutations in PDGFRA (Curtin et al.,
2006). To address fully the role of
PDGFRA in melanoma, we analyzed a
larger set of primary melanomas for
mutations, copy number increases, and
expression of PDGFRA. To increase the
likelihood of encountering mutations,
we enriched the samples for cases that
did not have mutations of KIT or BRAF.
Specifically, we analyzed DNA ex-
tracted from archival paraffin-em-
bedded primary melanomas with an
invasive component in which tumor
cells predominated over stroma cells.
Additional analyses on some of these
cases were reported previously (Curtin
et al., 2005, 2006). Institutional Review
Board of the University of California,
San Francisco, approved the study.
From a cohort of 102, we sequenced
the 26 primary melanomas which had
increased copy number of the 4q12
locus harboring PDGFRA (n¼ 10) or
had normal copy number but did not
show mutations in KIT exons 11, 13,
17, and 18, and BRAF exon 15 (n¼ 16).
Seven of the cases were acral melano-
mas, that is melanomas from the palms,
soles, and subungual sites; 13 were
mucosal melanomas; and three were
melanomas from chronically sun-
damaged skin, and three melanoma
from skin without chronic sun damage.
CSD was defined by the microscopic
presence or absence of marked solar
elastosis of the dermis surrounding the
melanomas. Exons of interest were
amplified by PCR and sequenced as
described previously (Curtin et al.,
2005) using specific primers flanking
the common (Heinrich et al., 2003b)
mutation sites of PDGFRA; exons 10,
12, 14, and 18 (Table S1). No mutations
of PDGFRA were found in any or our
melanoma samples. Our samples con-
tained a majority of tumor cells, which
excludes the possibility that mutations
were missed owing to an excess of
stromal cells. In addition, all samples
included in this analysis showed DNA
copy number changes by CGH (Curtin
et al., 2005, 2006), which indicates that
Abbreviations: CSD, chronic sun damage; KIT, v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene
homolog; NRAS, neuroblastoma ras viral oncogene homolog; PDGFRA, platelet-derived growth factor a
receptor
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the DNA was extracted from a suffi-
ciently pure, clonally related tumor cell
population. It should also be noted that
over a third of our samples had multiple
copies of the 4q12 locus. These copy
number increases are expected to affect
selectively any mutated allele as we
have demonstrated previously for KIT
(Curtin et al., 2006) and BRAF (Mal-
donado et al., 2003). The increased
dosage of the mutated allele allows the
detection of such mutations even in a
significant excess of normal cells. We
cannot exclude the possibility that
undetected mutations may be present
in a minority of cells; however, the
relevance of such mutations would be
unclear as these cells would not have
been clonally selected. In situ hybridi-
zation for PDGFRA mRNA was per-
formed on 14 samples with adequate
residual sample. Increased PDGFRA
expression was observed in 5/14 sam-
ples, but was not linked to increased
copy number of the 4q12 locus (Table
S2). The absence of PDGFRA mutations
in melanomas with and without in-
creased copy number of 4q12 in
melanomas without other known mito-
gen-activated protein kinase abnormal-
ities, together with our previous
observation that KIT mutations are
commonly found in melanomas of the
acral, mucosal and CSD types, suggests
that KIT and not PDGFRA is the
relevant gene in melanoma that drives
the selection of copy number increases
of the locus. Whether the increased
expression of PDGFRA that occurs in
some melanomas can be exploited
therapeutically needs to be shown.
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TO THE EDITOR
The association between infection by
the human T-cell lymphotropic virus
types 1 (HTLV-1) and 2 (HTLV-2) and
the most common form of cutaneous
T-cell lymphoma called mycosis fun-
goides (MF), along with its leukemic
variant called Se´zary syndrome (SS), is
unclear. In both MF and SS, antibodies
against HTLV-1 structural proteins and
HTLV-1/-2 DNA sequences have been
detected in peripheral blood mono-
nuclear cells (PBMCs), cutaneous biop-
sies (Hall et al., 1991; Whittaker and
Luzzatto, 1993; Zucker-Franklin,
Abbreviations: HTLV-1/2, human T-cell lymphotropic virus type 1/type 2; MF, mycosis fungoides;
SS, Se´zary syndrome
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